Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/12/2018 |
| Start Date: | October 2016 |
| End Date: | October 2020 |
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
The objective of this study is to evaluate long-term safety and efficacy of caplacizumab, to
evaluate safety and efficacy of repeated use of caplacizumab and to characterize long term
impact of TTP.
evaluate safety and efficacy of repeated use of caplacizumab and to characterize long term
impact of TTP.
Inclusion Criteria:
1. Completed the Final (28 day) FU visit in Study ALX0681-C301.
2. Is ≥18 years of age at the time of signing the informed consent form (ICF).
3. Provided informed consent prior to initiation of any study specific
activity/procedure.
Exclusion Criteria:
1. Not being able/willing to comply with the study protocol procedures.
2. Currently enrolled in a clinical study with another investigational drug or device.
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials